Respiratory
1 drug is in development for Long COVID.
- Companies
- 1
- Clinical trials
- 13
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Long COVID pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Anktiva | ImmunityBio, Inc. (IBRX) |
About this indication
Long COVID context
Respiratory·MeSH: Post-Acute COVID-19 Syndrome (D000094024)
Also known as: Long Haul COVID-19, Long-Haul COVID, PASC Post Acute Sequelae of COVID-19, Post Acute COVID-19 Syndrome, Post COVID-19 Syndrome, Post-Acute COVID-19 Sequelae, Post-Acute Sequelae of COVID-19, Post-Acute Sequelae of SARS-CoV-2 Infection, Post-COVID Conditions
Frequently asked questions
How many drugs are in development for Long COVID?
BioSniper tracks 1 drug in development for Long COVID across 1 company.
How many clinical trials target Long COVID?
There are 13 clinical trials targeting Long COVID tracked by BioSniper.